Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Who is shorting????

<< Previous

Bullboard Posts

Next >>

Comment by Cb27743on Jun 21, 2021 3:18pm

116 Views

Post# 33421536

RE:RE:RE:RE:RE:Who is shorting????

Feeling the frustration, the momentum killer/seller is annoying af. If phase 2 results are positive with news of a fast track trial, this will blast off IMO. Would be even better in the future if they were listed on a US exchange outside of the OTC. As shared previously on this board, this is all about targetting organ inflammation. With positive results, this will be the door to an open to a multi-billion dollar market.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China